Skip to main content
PMC home page
Sarcoma logoLink to Sarcoma
. 2001 Mar;5(1):9–15. doi: 10.1080/13577140120048890

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols

R Beverly Raney 1,10,✉, Harold M Maurer 2, James R Anderson 3, Richard J Andrassy 4, Sarah S Donaldson 5, Stephen J Qualman 6, Moody D Wharam 7, Eugene S Wiener 8, William M Crist 9
PMCID: PMC2395450  PMID: 18521303

Abstract

Purpose. To enumerate lessons from studying 4292 patients with rhabdomyosarcoma (RMS) in the Intergroup Rhabdomyosarcoma Study Group (IRSG, 1972–1997).

Patients. Untreated patients < 21 years of age at diagnosis received systemic chemotherapy, with or without irradiation (XRT) and/or surgical removal of the tumor.

Methods. Pathologic materials and treatment were reviewed to ascertain compliance and to confirm response and relapse status.

Results. Survival at 5 years increased from 55 to 71% over the period. Important lessons include the fact that extent of disease at diagnosis affects prognosis. Re-excising an incompletely removed tumor is worthwhile if acceptable form and function can be preserved. The eye, vagina, and bladder can usually be saved. XRT is not necessary for children with localized, completely excised embryonal RMS. Hyperfractionated XRT has thus far not produced superior local control rates compared with conventional, once-daily XRT. Patients with non-metastatic cranial parameningeal sarcoma can usually be cured with localized XRT and systemic chemotherapy, without whole-brain XRT and intrathecal drugs. Adding doxorubicin, cisplatin, etoposide, and ifosfamide has not significantly improved survival of patients with gross residual or metastatic disease beyond that achieved with VAC (vincristine, actinomycin D, cyclophosphamide) and XRT. Most patients with alveolar RMS have a tumor-specific translocation. Mature rhabdomyoblasts after treatment of patients with bladder rhabdomyosarcoma are not necessarily malignant, provided that the tumor has shrunk and malignant cells have disappeared.

Discussion. Current IRSG-V protocols, summarized herein, incorporate recommendations for risk-based management. Two new agents, topotecan and irinotecan, are under investigation for patients who have an intermediate or high risk of recurrence.

Full Text

The Full Text of this article is available as a PDF (118.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arndt C., Tefft M., Gehan E., Anderson J., Jenson M., Link M., Donaldson S., Breneman J., Wiener E., Webber B. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):124–129. doi: 10.1097/00043426-199703000-00005. [DOI] [PubMed] [Google Scholar]
  2. Barr F. G. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):483–491. doi: 10.1097/00043426-199711000-00001. [DOI] [PubMed] [Google Scholar]
  3. Crist W. M., Garnsey L., Beltangady M. S., Gehan E., Ruymann F., Webber B., Hays D. M., Wharam M., Maurer H. M. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol. 1990 Mar;8(3):443–452. doi: 10.1200/JCO.1990.8.3.443. [DOI] [PubMed] [Google Scholar]
  4. Crist W., Gehan E. A., Ragab A. H., Dickman P. S., Donaldson S. S., Fryer C., Hammond D., Hays D. M., Herrmann J., Heyn R. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995 Mar;13(3):610–630. doi: 10.1200/JCO.1995.13.3.610. [DOI] [PubMed] [Google Scholar]
  5. Hays D. M., Lawrence W., Jr, Wharam M., Newton W., Jr, Ruymann F. B., Beltangady M., Maurer H. M. Primary reexcision for patients with 'microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg. 1989 Jan;24(1):5–10. doi: 10.1016/s0022-3468(89)80290-8. [DOI] [PubMed] [Google Scholar]
  6. Heyn R., Haeberlen V., Newton W. A., Ragab A. H., Raney R. B., Tefft M., Wharam M., Ensign L. G., Maurer H. M. Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol. 1993 Feb;11(2):262–270. doi: 10.1200/JCO.1993.11.2.262. [DOI] [PubMed] [Google Scholar]
  7. Heyn R., Khan F., Ensign L. G., Donaldson S. S., Ruymann F., Smith M. A., Vietti T., Maurer H. M. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol. 1994;23(2):99–106. doi: 10.1002/mpo.2950230206. [DOI] [PubMed] [Google Scholar]
  8. Heyn R., Newton W. A., Raney R. B., Hamoudi A., Bagwell C., Vietti T., Wharam M., Gehan E., Maurer H. M. Preservation of the bladder in patients with rhabdomyosarcoma. J Clin Oncol. 1997 Jan;15(1):69–75. doi: 10.1200/JCO.1997.15.1.69. [DOI] [PubMed] [Google Scholar]
  9. Kelly K. M., Womer R. B., Sorensen P. H., Xiong Q. B., Barr F. G. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol. 1997 May;15(5):1831–1836. doi: 10.1200/JCO.1997.15.5.1831. [DOI] [PubMed] [Google Scholar]
  10. Kuttesch J. F., Parham D. M., Luo X., Meyer W. H., Bowman L., Shapiro D. N., Pappo A. S., Crist W. M., Beck W. T., Houghton P. J. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol. 1996 Mar;14(3):886–900. doi: 10.1200/JCO.1996.14.3.886. [DOI] [PubMed] [Google Scholar]
  11. Lawrence W., Jr, Anderson J. R., Gehan E. A., Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer. 1997 Sep 15;80(6):1165–1170. [PubMed] [Google Scholar]
  12. Lawrence W., Jr, Hays D. M., Heyn R., Beltangady M., Maurer H. M. Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors. World J Surg. 1988 Oct;12(5):676–684. doi: 10.1007/BF01655884. [DOI] [PubMed] [Google Scholar]
  13. Malkin D., Li F. P., Strong L. C., Fraumeni J. F., Jr, Nelson C. E., Kim D. H., Kassel J., Gryka M. A., Bischoff F. Z., Tainsky M. A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990 Nov 30;250(4985):1233–1238. doi: 10.1126/science.1978757. [DOI] [PubMed] [Google Scholar]
  14. Mandell L., Ghavimi F., LaQuaglia M., Exelby P. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol. 1990;18(6):466–471. doi: 10.1002/mpo.2950180606. [DOI] [PubMed] [Google Scholar]
  15. Maurer H. M., Beltangady M., Gehan E. A., Crist W., Hammond D., Hays D. M., Heyn R., Lawrence W., Newton W., Ortega J. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988 Jan 15;61(2):209–220. doi: 10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  16. Maurer H. M., Gehan E. A., Beltangady M., Crist W., Dickman P. S., Donaldson S. S., Fryer C., Hammond D., Hays D. M., Herrmann J. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993 Mar 1;71(5):1904–1922. doi: 10.1002/1097-0142(19930301)71:5<1904::aid-cncr2820710530>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  17. Neville H. L., Andrassy R. J., Lally K. P., Corpron C., Ross M. I. Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg. 2000 Jun;35(6):961–964. doi: 10.1053/jpsu.2000.6936. [DOI] [PubMed] [Google Scholar]
  18. Newton W. A., Jr, Soule E. H., Hamoudi A. B., Reiman H. M., Shimada H., Beltangady M., Maurer H. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol. 1988 Jan;6(1):67–75. doi: 10.1200/JCO.1988.6.1.67. [DOI] [PubMed] [Google Scholar]
  19. Pappo A. S., Lyden E., Breneman J., Wiener E., Teot L., Meza J., Crist W., Vietti T. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J Clin Oncol. 2001 Jan 1;19(1):213–219. doi: 10.1200/JCO.2001.19.1.213. [DOI] [PubMed] [Google Scholar]
  20. Ruymann F. B., Vietti T., Gehan E., Wiener E., Wharam M., Newton W. A., Jr, Maurer H. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol Oncol. 1995 Nov;17(4):331–337. doi: 10.1097/00043426-199511000-00009. [DOI] [PubMed] [Google Scholar]
  21. Strong L. C., Williams W. R., Tainsky M. A. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol. 1992 Jan 15;135(2):190–199. doi: 10.1093/oxfordjournals.aje.a116271. [DOI] [PubMed] [Google Scholar]
  22. Wolden S. L., Anderson J. R., Crist W. M., Breneman J. C., Wharam M. D., Jr, Wiener E. S., Qualman S. J., Donaldson S. S. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol. 1999 Nov;17(11):3468–3475. doi: 10.1200/JCO.1999.17.11.3468. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES